Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical significance of personalized tacrolimus dosing by adjusting to donor CYP3A-status in liver transplant recipients.

British journal of clinical pharmacology - 1 Apr 2021

Csikány Nóra, Kiss Ádám, Déri Máté, Fekete Ferenc, Minus Annamária, Tóth Katalin, Temesvári Manna, Sárváry Enikő, Bihari László, Gerlei Zsuzsa, Kóbori László, Monostory Katalin

Abstract excerpt

Donor's CYP3A-status (CYP3A5 genotype and CYP3A4 expression) can provide prognostic information regarding tacrolimus-metabolizing capacity of the liver graft and initial tacrolimus dosing for therapeutic blood concentrations in liver transplants. The present work prospectively investigated whether CYP3A-status guided tacrolimus therapy has any potential clinical benefit for recipients in the early postoperative...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP3A
Share to Genotype

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Graft Rejection

Share to Immunosuppressive Agents

Share to Liver Transplantation

Share to Tacrolimus

Share to Transplant Recipients

Source

Identifiers

PMID: 32986876
DOI: 10.1111/bcp.14566

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical significance of personalized tacrolimus dosing by adjusting to donor CYP3A-status in liver transplant recipients.PMID 32986876Read ↗

Dosing tacrolimus based on CYP3A5 genotype: will it improve clinical outcome?Semantic proximity Read ↗

Clinical Impact of the Adaptation of Initial Tacrolimus Dosing to the CYP3A5 Genotype After Kidney Transplantation: Systematic Review and Meta-Analysis of Randomized Controlled Trials.Semantic proximity Read ↗

The CYP3A5 genotypes of both liver transplant recipients and donors influence the time‐dependent recovery of tacrolimus clearance during the early stage following transplantationSemantic proximity Read ↗

Effect of CYP3A5 genotype on renal allograft recipients treated with tacrolimus.Semantic proximity Read ↗

Personalized immunosuppression after kidney transplantation.Semantic proximity Read ↗

Association between tacrolimus concentration and genetic polymorphisms of CYP3A5 and ABCB1 during the early stage after liver transplant in an Iranian population.Semantic proximity Read ↗

Tacrolimus Therapeutic Drug Monitoring in Stable Kidney Transplantation and Individuation of CYP3A5 Genotype.Semantic proximity Read ↗

Effect of CYP3A5*1 expression on tacrolimus required dose after liver transplantation: A systematic review and meta-analysis.Semantic proximity Read ↗

The influence of pharmacogenetics on the time to achieve target tacrolimus concentrations after kidney transplantation.Semantic proximity Read ↗

[Pharmacogenetics of tacrolimus: from bench to bedside?].Semantic proximity Read ↗

Benefits of minimizing immunosuppressive dosage according to cytochrome P450 3A5 genotype in liver transplant patients: findings from a single-center study.Semantic proximity Read ↗

[Factors affecting the pharmacokinetics after living donor liver transplant].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.